Human cytomegalovirus neutralising antibodies and increased risk of coronary artery disease in Indian population
暂无分享,去创建一个
V. Kakkar | Lakshmi A Mundkur | V. Endrész | M. Varma | Veena S. Rao | Sridhara Hebbagudi | Hemapriys Shivanandan | E. Gonczol | L. Mundkur
[1] B. Nallamothu,et al. Systems of care for ST-elevation myocardial infarction in India , 2011, Heart.
[2] J. Pell,et al. Prevention of cardiovascular disease in a rural region of India and strategies to address the unmet need , 2011, Heart.
[3] V. Kakkar,et al. Rationale, design & preliminary findings of the Indian Atherosclerosis Research Study. , 2010, Indian heart journal.
[4] C. Sinzger,et al. Endothelial cells in human cytomegalovirus infection: One host cell out of many or a crucial target for virus spread? , 2009, Thrombosis and Haemostasis.
[5] M. Burnett,et al. Insights Into the Role of Infection in Atherogenesis and in Plaque Rupture , 2009, Circulation.
[6] Anders Larsson,et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.
[7] V. Singh,et al. Reducing the burden of coronary artery disease in India: challenges and opportunities. , 2008, Indian heart journal.
[8] B. Asselain,et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. , 2005, Journal of the American College of Cardiology.
[9] A. Dogan,et al. Are the high levels of cytomegalovirus antibodies a determinant in the development of coronary artery disease? , 2005, International heart journal.
[10] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[11] S. Awasthi,et al. Burden of infectious diseases in South Asia , 2004, BMJ : British Medical Journal.
[12] D. Girelli,et al. Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis , 2003, The Lancet.
[13] C. Visser,et al. Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? , 2003, Cardiovascular research.
[14] Fred Wang,et al. Direct Relationship between Suppression of Virus-Specific Immunity and Emergence of Cytomegalovirus Disease in Simian AIDS , 2003, Journal of Virology.
[15] M. Burnett,et al. IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. , 2003, Atherosclerosis.
[16] D. Levy,et al. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. , 2002, Journal of the American College of Cardiology.
[17] W. Jaross,et al. Biological effects of secretory phospholipase A2 group IIA on lipoproteins and in atherogenesis , 2002, European journal of clinical investigation.
[18] D. Bouley,et al. Murine Cytomegalovirus CC Chemokine Homolog MCK-2 (m131-129) Is a Determinant of Dissemination That Increases Inflammation at Initial Sites of Infection , 2001, Journal of Virology.
[19] M. Burnett,et al. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. , 2001, Atherosclerosis.
[20] K. Radsak,et al. Use of recombinant glycoprotein antigens gB and gH for diagnosis of primary human cytomegalovirus infection during pregnancy * , 2001, Journal of medical virology.
[21] M. Eggers,et al. Combination of microneutralization and avidity assays: Improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy , 2000, Journal of medical virology.
[22] W. Jaross,et al. Expression of secretory group IIA phospholipase A(2) in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[23] A. Quyyumi,et al. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. , 1999, Journal of the American College of Cardiology.
[24] T. Schall,et al. Cytomegalovirus encodes a potent alpha chemokine. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Danesh,et al. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease , 1999, Heart.
[26] W. Gibson,et al. Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles. , 1996, Virology.
[27] R. Ricciardi,et al. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. , 1990, The Journal of infectious diseases.
[28] S. Plotkin,et al. A rapid microneutralization assay for cytomegalovirus. , 1986, Journal of virological methods.
[29] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[30] G. Vetrovec,et al. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. , 1998, The Journal of infectious diseases.